Five percent of gynecologic cancers are clear cell cancers. About half of clear cell cancers affecting the ovaries or endometrium (uterine lining) have a faulty version of a protein called BAF250a. Normal BAF250a keeps healthy cells from becoming cancer cells. BAF250s that does not function well may lead to cancer growth.
Laboratory studies have shown that dasatinib is effective against ovarian and endometrial cancer cells that have an altered version of the BAF250a protein. In this Gynecologic Oncology Group study, researchers are evaluating the safety and effectiveness of dasatinib in women with clear cell cancer of the ovaries, fallopian tubes, peritoneum, or endometrium whose cancer has persisted or returned despite standard therapy.
Dasatinib is already approved for treating a type of leukemia; its use in this study is considered investigational. It is a pill that is taken orally (by mouth).